Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy

Cellular Immunology

Volumn 285, Issue 1-2, 2013, Pages 111-117

  Lu, Miao ^a   Xia, Zhi Yang ^a   Bao, Lang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

BCG; Delayed type hypersensitivity; Immunogenicity; Pathogen microorganism

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 4; SUBUNIT VACCINE;

ANTIBACTERIAL ACTIVITY; ANTIBODY RESPONSE; ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SPLEEN CELL; TH1 CELL;

BACILLE CALMETTE-GUÉRIN; BCC-C; BCG; BCG-C+P69, BCG-C+PRO69; BCG-C+P72, BCG-C+PRO72; BCG-C+PP, BCG-C+PRO-PET; BCG-P; BCG-P+P69, BCG-P+PRO69; BCG-P+P72, BCG-P+PRO72; BCG-P+PP, BCG-P+PRO-PET; DELAYED TYPE HYPERSENSITIVITY; IMMUNOGENICITY; PATHOGEN MICROORGANISM; THE GROUP IMMUNIZED BCG- PASTEUR1173 PRIME PROTEIN PET32 (A+) PLASMID BOOST; THE GROUP IMMUNIZED BCG- PASTEUR1173 PRIME PROTEIN RV1769 BOOST; THE GROUP IMMUNIZED BCG- PASTEUR1173 PRIME PROTEIN RV1772 BOOST; THE GROUP IMMUNIZED BCG-CHINA PRIME PROTEIN PET32 (A+) PLASMID BOOST; THE GROUP IMMUNIZED BCG-CHINA PRIME PROTEIN RV1769 BOOST; THE GROUP IMMUNIZED BCG-CHINA PRIME PROTEIN RV1772 BOOST; THE GROUP IMMUNIZED WITH VACCINE BCG-CHINA SUB STRAIN; THE GROUP IMMUNIZED WITH VACCINE BCG-PASTEUR1173 SUB STRAIN;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; OPEN READING FRAMES; SPLEEN; TH1 CELLS; TUBERCULOSIS; VACCINATION;

EID: 84886811092     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.10.001     Document Type: Article

References (34)

1. World Health Organization WHO Report 2009: Global Tuberculosis Control-epidemiology, Strategy, Financing 2009, WHO, Geneva.
2. Brewer T.F. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin. Infect. Dis. 2000, 31:S64-S67.
3. Raviglione M.C. The TB epidemic from 1992 to 2002. Tuberculosis (Edinb.) 2002, 83(2003):4-14.
4. Liu Jun, Tran Vanessa, Leung Andrea S., Alexander David C., Zhu Baoli BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum. Vaccines 2009, 52:70-78.
5. Leung Andrea S., Tran Vanessa, Wu Zuowei, Yu Xuping, Alexander David C., Gao George Fu, Zhu Baoli, Liu Jun Novel genome polymorphisms in BCG vaccine strains and impact on efficacy. BMC Genom. 2008, 9:413.
6. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik G.K., Rane S., Small P.M. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999, 284:1520.
7. Cockle P.J., Gordon S.V., Lalvani A., Buddle B.M., Hewinson R.G., Vordermeier H.M. Identification of novel mycobacterium tuberculosis antigens with potential as diagnostic reagents or subunit vaccine candidates by comparative genomics. Infect. Immun. 2002, 70(12):6996-7003.
8. Mostowy Serge, Behr Marcel A. Comparative genomics in the fight against tuberculosis: diagnostics, epidemiology, and BCG vaccination. Am. J. Pharmacogenom. 2002, 23:189-196.
9. Sander C., McShane H. Translational mini-review series on vaccines:development and evaluation of improved vaccines against tuberculosis. Clin. Exp. Immunol. 2007, 147:401-411.
10. Cayabyab Mark J., Kashino Suely S., Campos-Neto Antonio Robust immune response elicited by a novel and unique Mycobacterium tuberculosis protein using an optimized DNA/protein heterologous prime/boost protocol. Immunology 2011, 135:216-225.
11. Gilberta Sarah C., Schneiderb Jörg, Hannanb Carolyn M., Hua Jiang Ting, Plebanskib Magdalena, Sindenc Robert, Hill Adrian V.S Enhanced CD8+ T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 2002, 207(8):1039-1045.
12. Martin Vordermeier H., Rhodes Shelley G., Dean Gillian, Goonetilleke Nilu, Huygen Kris, Hill Adrian V.S., Glyn Hewinson R., Gilbert Sarah C. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin. Immunology 2004, 1123:461-470.
13. Elvang Tara, Christensen Jan P., Billeskov Rolf, Hoang Truc Thi Kim Thanh, Holst Peter, Thomsen Allan Randrup, Andersen Peter, Dietrich Jes CD4+ and CD8+ T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS One 2009, 44:e5139.
14. You Qingrui, Yongge Wu, Yang Wu, Wei Wei, Wang Changyong, Jiang Dehua, Xianghui Yu, Zhang Xizhen, Wang Yong, Tang Zhijiao, Jiang Chunlai, Kong Wei Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis. Int. J. Infect. Dis. 2012, 16:e816-e825.
15. Martín Carlos, Bigi Fabiana, Gicquel Brigitte New vaccines against tuberculosis. Tuberculosis 2007, 10:341-360.
16. Davoudi Setareh, Rasoolinegad Mehrnaz, Younesian Masoud, et al. CD4+ cell counts in patients with different clinical manifestations of tuberculosis. Braz. J. Infect. Dis. 2008, 12:6.
17. van Crevel Reinout, Karyadi Elvina, Preyers Frank, Leenders Marij, Kullberg Bart-Jan, Ronald H, Nelwan Ronald H.H., van der Meer Jos W.M. Increased production of interleukin 4 by CD4+ and CD8+T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J. Infect. Dis. 1813, 2000:1194-1197.
18. Serbina Natalya V., Flynn Jo Anne L. Early emergence of cd8+t cells primed for production of type 1 cytokines in the lungs of Mycobacterium tuberculosis-infected mice. Infect. Immun. 1999, 678:3980-3988.
19. Inwald Jacqueline, Jahans Keith, Glyn Hewinson R., Gordon Stephen V. Inactivation of the Mycobacterium bovis homologue of the polymorphic RD1 gene Rv3879c (Mb3909c) does not affect virulence. Tuberculosis 2003, 83(6):387-393.
20. Majlessi Laleh, Simsova Marcela, Jarvis Zdenka, et al. An increase in antimycobacterial Th1-Cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. Infect. Immun. 2006, 2128-2137.
21. Mustafa A.S., Skeiky Y.A., Al-Attiyah R., Hewinson R.G. Immunogenicity of Mycobacterium tuberculosis antigens in Mycobacterium bovis BCG-vaccinated and M. bovis-infected cattle. Infect. Immun. 2006, 74(8):4566-4572.
22. Kumar Gavish., Dagur Pradeep Kumar, Singh Prashant Kumar, Shankar Hari, Yadav Virendra S., Katoch Vishwa M., Bajaj Bharat, Gupta Rajesh, Sengupta Utpal, Joshi Beenu Serodiagnostic efficacy of Mycobacterium tuberculosis 30/32-kDa mycolyl transferase complex, ESAT-6, and CFP-10 in patients with active tuberculosis. Arch. Immunol. Ther. Exp. 2010, 58:57-65.
23. Zhou Qing Feng, Luo Xue Gang, Ye Liang, Xi Tao High-level production of a novel antimicrobial peptide perinerin in Escherichia coli by fusion expression. Curr. Microbiol. 2007, 54:366-370.
24. *His-Ni-NTA chromatography as a superior technique in recombinant protein expression/purification. Protoc. Gene Anal. Methods Mol. Biol. 1994, 31:371-387.
25. Jia Lu., Wang Chun, Zhou Zhiguang, Zhang Ying, Cao Tingting, Shi Chunwei, Chen Zhenhua, Chen Lingxia, Cai Changxue, Fan Xionglin Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein. Clin. Dev. Immun. 2011, 10.1155/2011/617892.
26. Tanghe A.S.D., Souza V., Rosseels O., Denis T.H., Ottenhoff W., Dalemans C., Wheeler K.Huygen Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect. Immun. 2001, 69:3041-3047.
27. + T-cell epitopes from antigen 85A. Infect. Immun. 2002, 70:1623-1626.
28. Kennedy Nicholas J., Spithill Terry W., Tennent Jan, Wood Paul R., Piedrafita David DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance immunogenicity in a DNA prime/protein boost strategy. Vaccine 2002, 24:970-979.
29. Brooks J.V., Frank A.A., Keen M.A., Bellisle J.T., Orme I.M. Boosting vaccine for tuberculosis. Infect. Immun. 2001, 69:2714-2717.
30. + T cells correlate with active Mycobacterium tuberculosis infection. Eur. J. Immunol. 2010, 40:2211-2220.
31. + T cells in tuberculosis. Am. J. Respir. Crit. Care Med. 2002, 166:1116-1121.
32. Munk M.E., Emoto M. Functions of T-cell subsets and cytokines in mycobacterial infections. Eur. Respir. J. Suppl. 1995, 20:68s-75s.
33. + T cells to control of Mycobacterium tuberculosis infection. J. Immunol. 2006, 176:4296-4314.
34. McShane Helen, Hill Adrian Prime-boost immunisation strategies for tuberculosis. Microbes Infect. 2005, 7:962-967.